RNA, Small Interfering
"RNA, Small Interfering" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Descriptor ID |
D034741
|
MeSH Number(s) |
D13.150.650.700 D13.444.735.150.700 D13.444.735.790.552.875
|
Concept/Terms |
RNA, Small Interfering- RNA, Small Interfering
- Interfering RNA, Small
- Short Interfering RNA
- Interfering RNA, Short
- RNA, Short Interfering
- Small Interfering RNA
- siRNA
Piwi-Interacting RNA- Piwi-Interacting RNA
- Piwi Interacting RNA
- RNA, Piwi-Interacting
- RNA, Piwi Interacting
- piRNA
Short Hairpin RNA- Short Hairpin RNA
- Hairpin RNA, Short
- RNA, Short Hairpin
- Small Hairpin RNA
- Hairpin RNA, Small
- RNA, Small Hairpin
- shRNA
Repeat-Associated siRNA- Repeat-Associated siRNA
- Repeat Associated siRNA
- siRNA, Repeat-Associated
- siRNA, Repeat Associated
Scan RNA- Scan RNA
- scnRNA
- Small Scan RNA
- RNA, Small Scan
- Scan RNA, Small
- RNA, Scan
Trans-Acting siRNA- Trans-Acting siRNA
- Trans Acting siRNA
- tasiRNA
- siRNA, Trans-Acting
- siRNA, Trans Acting
|
Below are MeSH descriptors whose meaning is more general than "RNA, Small Interfering".
Below are MeSH descriptors whose meaning is more specific than "RNA, Small Interfering".
This graph shows the total number of publications written about "RNA, Small Interfering" by people in this website by year, and whether "RNA, Small Interfering" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 2 | 2 | 2003 | 2 | 3 | 5 | 2004 | 1 | 11 | 12 | 2005 | 0 | 9 | 9 | 2006 | 1 | 12 | 13 | 2007 | 2 | 11 | 13 | 2008 | 5 | 23 | 28 | 2009 | 5 | 21 | 26 | 2010 | 4 | 16 | 20 | 2011 | 6 | 30 | 36 | 2012 | 7 | 34 | 41 | 2013 | 3 | 32 | 35 | 2014 | 6 | 20 | 26 | 2015 | 4 | 17 | 21 | 2016 | 3 | 18 | 21 | 2017 | 1 | 16 | 17 | 2018 | 1 | 14 | 15 | 2019 | 2 | 11 | 13 | 2020 | 2 | 10 | 12 | 2021 | 2 | 6 | 8 | 2022 | 1 | 5 | 6 | 2023 | 0 | 10 | 10 | 2024 | 4 | 6 | 10 | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "RNA, Small Interfering" by people in Profiles.
-
Timic Stamenic T, Feseha S, Fine-Raquet B, Tadic VP, Todorovic SM. In vivo silencing of the thalamic CaV3.1 voltage-gated calcium channels demonstrates their region-specific role in anesthetic mediated hypnosis. Exp Biol Med (Maywood). 2025; 250:10553.
-
Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, Szarek M, Stroes ESG, Troquay R, Dorresteijn JAN, Fok H, Rider DA, Romano S, Wolski K, Rambaran C. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024 12 17; 332(23):1992-2002.
-
Sanati M, Figueroa-Espada CG, Han EL, Mitchell MJ, Yavari SA. Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers. ACS Nano. 2024 12 24; 18(51):34425-34463.
-
Jogdeo CM, Panja S, Kumari N, Tang W, Kapoor E, Siddhanta K, Das A, Boesen EI, Foster KW, Oupick? D. Inulin-based nanoparticles for targeted siRNA delivery in acute kidney injury. J Control Release. 2024 Dec; 376:577-592.
-
Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 Oct 14; 120(12):1400-1410.
-
Adhikari B, Stager MA, Collins EG, Fischenich KM, Olusoji J, Ruble AF, Payne KA, Krebs MD. Sustained release of MAPK14-targeting siRNA from polyelectrolyte complex hydrogels mitigates MSC osteogenesis in vitro with potential application in growth plate injury. J Biomed Mater Res A. 2024 12; 112(12):2346-2357.
-
Brugarolas J, Obara G, Beckermann KE, Rini B, Lam ET, Hamilton J, Schluep T, Yi M, Wong S, Mao ZL, Gamelin E, Tannir NM. A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2a in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2024 Jun 03; 30(11):2402-2411.
-
Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, Han J, Conde LG, Wright RS. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
-
Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, Binns CA, MacBeth M, Whitty PA, Diamond JR, Pitts TM. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis. Breast Cancer Res. 2024 03 01; 26(1):35.
-
Cox AA, Liu A, Ng CJ. Clusterin knockdown has effects on intracellular and secreted von Willebrand factor in human umbilical vein endothelial cells. PLoS One. 2024; 19(2):e0298133.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|